Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis
Clicks: 293
ID: 115341
2015
Vedolizumab is superior to placebo as induction and maintenance therapy for ulcerative colitis. Future studies are needed to define long-term efficacy and safety of this agent.
| Reference Key |
mh2015inflammatoryvedolizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mosli MH;MacDonald JK;Bickston SJ;Behm BW;Tsoulis DJ;Cheng J;Khanna R;Feagan BG;; |
| Journal | inflammatory bowel diseases |
| Year | 2015 |
| DOI | DOI not found |
| URL | |
| Keywords |
systematic review
meta-analysis
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
prognosis
research support
non-u.s. gov't
Remission Induction
Antibodies
Monoclonal
Brian G Feagan
Humanized / therapeutic use*
Colitis
Ulcerative / drug therapy*
Gastrointestinal Agents / therapeutic use*
induction chemotherapy
maintenance chemotherapy
pmid:25844963
doi:10.1097/mib.0000000000000396
mahmoud h mosli
john k macdonald
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.